Every Form 4 that Amylyx Pharmaceuticals (AMLX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AMLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMLX filings page.
Amylyx Pharmaceuticals, Inc. (AMLX) director Karen Firestone reported exercising stock options to acquire common shares on August 31, 2026. She exercised two fully vested stock option grants covering a total of 50,000 shares of Common Stock, at exercise prices of $1.76 and $5.05 per share, respectively. The filing does not show her post-transaction share balances, and no Rule 10b5-1 trading plan is reported.
Amylyx Pharmaceuticals, Inc. (symbol: AMLX) is the issuer of record for a Form 4 filing submitted to the SEC.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Justin B. Klee acquired 60,039 shares of Common Stock on August 18, 2026 through a grant classified as a performance-based award. The shares are represented by performance share units that vested on that date. Following this award, Klee directly holds 3,643,520 shares of Amylyx Pharmaceuticals Common Stock.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Legal Officer Gina Mazzariello acquired additional equity-based compensation. On August 18, 2026, she received 21,284 shares of Common Stock represented by performance share units (PSUs) that were awarded upon the achievement of certain performance metrics and vested on that date. Following this award, she directly holds 200,374 shares of Amylyx Pharmaceuticals common stock.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Medical Officer Camille L. Bedrosian acquired 22,807 shares of common stock through a compensation-related grant. The shares are represented by performance share units (PSUs) that were awarded upon achievement of specified performance metrics and vested on August 18, 2026. Following this vesting, Bedrosian holds 288,092 common shares directly.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Joshua B. Cohen received an equity award linked to company performance. On August 18, 2026, he acquired 60,039 shares of Common Stock represented by performance share units (PSUs) that vested on that date upon achievement of specified performance metrics. Following this vesting event, Cohen directly holds 3,643,587 shares of Amylyx Common Stock.
Amylyx Pharmaceuticals, Inc. insider Gina Mazzariello, Chief Legal Officer, reported two open-market sales of common stock. On July 9, 2026, she sold 15,000 shares at a weighted average price of $18.3164 per share, and on July 10, 2026 she sold another 15,000 shares at a weighted average price of $17.6081 per share. The filing states that these sales were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026. Following the transactions, she holds 179,090 shares of Amylyx Pharmaceuticals common stock directly.
Amylyx Pharmaceuticals director Bernhardt G. Zeiher received a grant of 24,372 stock options. These options give the right to buy 24,372 shares of Amylyx common stock at an exercise price of $14.31 per share and expire on June 3, 2036.
According to the terms, the options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as the director remains in continuous service with the company through that vesting date. After this grant, the director holds 24,372 derivative securities directly.
Amylyx Pharmaceuticals director Karen Firestone received a grant of stock options covering 24,372 shares of common stock at an exercise price of $14.31 per share. These options vest in full on the earlier of June 4, 2027 or the next annual meeting, provided she remains in continuous service, and bring her directly held option position reported in this filing to 24,372 shares.
Amylyx Pharmaceuticals director Daphne Quimi received a stock option grant covering 24,372 shares of Common Stock. The option has an exercise price of $14.31 per share and expires on June 3, 2036. It vests in full on the earlier of June 4, 2027 or the next annual meeting, subject to her continuous service, and represents her entire reported option position in this filing.
Amylyx Pharmaceuticals director George M. Milne Jr. received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or the next annual meeting, as long as he continues serving the company.
Amylyx Pharmaceuticals director Paul R. Fonteyne received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and were awarded at no cost to him as compensation.
These options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as he continues serving the company through that date. After this grant, he holds 24,372 stock options directly.
Amylyx Pharmaceuticals director Karen Firestone made an open-market purchase of the company’s Common Stock. On May 21, 2026, she bought 3,800 shares at a price of $13.51 per share. Following this transaction, she directly owns 66,900 shares of Amylyx common stock.
Cohen Joshua B reported acquisition or exercise transactions in this Form 4 filing.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported equity awards consisting of 248,865 shares of common stock from a restricted stock unit grant and a stock option covering 373,295 shares. The RSUs vest in four equal annual installments starting on March 1, 2027, while 25% of the option vests on that date and the remainder vests monthly over the following 36 months, all subject to his continued service.
Amylyx Pharmaceuticals Chief Legal Officer receives new equity awards. On March 5, 2026, Gina Mazzariello was granted stock options for 111,990 shares at an exercise price of $0.00 per share and an award of 74,660 shares of common stock in the form of restricted stock units.
The RSU award vests in four equal annual installments starting March 1, 2027, contingent on continued service. The stock option vests with 25% on March 1, 2027 and the remainder monthly over the next 36 months, also subject to continued service. Following these awards, she directly holds 209,090 shares of common stock.
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported equity compensation awards in the form of stock options and restricted stock units. On March 5, 2026, he was granted stock options for 143,985 shares at an exercise price of $0.00 per share, and a separate grant of 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to his continued service. Twenty‑five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also subject to continued service. Additional common shares are held indirectly by various family trusts for which he serves as trustee, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported equity awards from the company. He received a stock option for 373,295 shares at an exercise price of $0.0000 per share and a grant of 248,865 shares of common stock as restricted stock units (RSUs).
The RSUs vest in four equal annual installments starting on March 1, 2027, conditioned on his continued service. The option vests 25% on March 1, 2027, with the remaining shares vesting monthly over the next 36 months, also subject to continued service. After these grants, he reported owning 3,583,481 shares of common stock directly.
Amylyx Pharmaceuticals granted Chief Medical Officer Camille L. Bedrosian equity awards on March 5, 2026. She received stock options for 143,985 shares at an exercise price of $0.00 and 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to continued service. Twenty-five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also contingent on ongoing service.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported an open-market sale of common stock tied to tax withholding. On March 2, he sold 29,282 shares at a weighted average price of $14.4717 per share to cover withholding obligations from vesting restricted stock units. The filing notes these sales were automatic and not at his discretion, and he continued to hold 3,334,616 shares of Amylyx common stock directly after the transaction.
Amylyx Pharmaceuticals director and Co-CEO Joshua B. Cohen reported an automatic tax-related share sale. On March 2, 2026, 29,282 shares of common stock were sold at a weighted average price of $14.484 per share to cover tax withholding owed on vesting restricted stock units.
The filing notes these sales were required to satisfy withholding obligations and were not made at Cohen’s discretion. After the transaction, he continues to directly own 3,334,683 shares of Amylyx common stock, indicating he retains a substantial equity stake in the company.
Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian reported an automatic sale of 6,461 shares of common stock on March 2, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. The shares were sold at a weighted average price of $14.5806 per share in multiple trades between $14.440 and $14.945. After these tax-related sales, Bedrosian held 169,295 shares of Amylyx common stock directly.
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported an automatic share sale related to tax withholding. On March 2, 2026, he sold 7,909 shares of common stock in an open-market transaction at a weighted average price of $14.5216 per share to cover taxes from restricted stock unit vesting.
After this sale, he directly held 165,638 shares. The filing also notes indirect holdings through several trusts, including 100,000 shares, 15,459 shares and 11,072 shares, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of 6,844 shares of common stock on March 2, 2026 to cover tax withholding from vesting restricted stock units. The weighted average sale price was $14.5205 per share, and she held 134,430 shares afterward.
Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of company stock tied to tax withholding. On February 23, 2026, she sold 3,419 shares of common stock in open-market transactions at a weighted average price of $14.1422 per share. The filing explains these shares were sold automatically to cover tax obligations from the vesting of restricted stock units, not at her discretion. After these transactions, she beneficially owned 141,274 shares of Amylyx common stock.
Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates reported an automatic sale of common stock tied to equity compensation taxes. On February 2, 2026, he sold 3,557 shares of Amylyx common stock at a weighted average price of $14.6463 per share to cover tax withholding from vesting restricted stock units. After this transaction, he directly held 173,547 shares, with additional shares held in several family trusts where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported an automatic sale of common stock to cover taxes. On February 2, 2026, he sold 15,500 shares of Amylyx common stock at a weighted average price of $14.6834 per share.
The footnotes explain that these shares were required to be sold to satisfy tax withholding obligations from vested restricted stock units and were not sold at his discretion. After this tax-related sale, Cohen beneficially owned 3,363,965 shares of Amylyx common stock in direct ownership.
Amylyx Pharmaceuticals Chief Legal Officer reports automatic share sale for taxes. Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 3,448 shares of common stock on February 2, 2026 at a weighted average price of $14.6507 per share.
The footnotes state these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units and were not at her discretion. After this transaction, she directly holds 144,693 Amylyx common shares.
Amylyx Pharmaceuticals Co-CEO Justin B. Klee reported an automatic tax-related share sale. On 02/02/2026, he sold 15,500 shares of Amylyx common stock at a weighted average price of $14.685 per share to cover tax withholding tied to vesting restricted stock units.
After this transaction, Klee still beneficially owned 3,363,898 Amylyx shares directly. The filing notes the sales were required for tax withholding and were not made at his discretion, and that individual sale prices ranged from $14.510 to $14.760.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported option exercises and related share sales. On January 15, 2026, he exercised 197,182 stock options at $7.57 per share and sold 136,193 shares of common stock at a weighted average price of $13.5895. On January 16, 2026, he exercised an additional 2,818 stock options at $7.57 per share and sold 1,974 shares at a weighted average price of $13.8293. A footnote states that shares were sold to cover option cost and tax obligations under a preset sales plan adopted on November 12, 2025. After these transactions, Cohen directly beneficially owned 3,379,465 shares of Amylyx common stock.
Amylyx Pharmaceuticals Co-Chief Executive Officer and director Justin B. Klee reported option exercises and related share sales. On January 15, 2026, he exercised stock options for 197,153 shares of common stock at an exercise price of $7.57 per share, then sold 136,193 shares at a weighted average price of $13.5827 per share. On January 16, 2026, he exercised options for an additional 2,847 shares at $7.57 and sold 1,995 shares at a weighted average price of $13.8853 per share. According to the footnotes, these sales were made to cover option cost and tax obligations under a preset sales plan adopted on November 12, 2025. After these transactions, Klee directly held 3,379,398 shares of Amylyx common stock.
Amylyx Pharmaceuticals director reports stock gift. Director George M. Milne Jr filed a Form 4 showing a bona fide gift of 17,780 shares of Amylyx Pharmaceuticals, Inc. common stock on January 12, 2026. The shares were transferred for no consideration, meaning he did not receive payment for them. After this gift, he directly beneficially owned 812,881 shares of the company’s common stock.
Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates reported an automatic sale of common stock. On January 6, 2026, he sold 3,326 shares of Amylyx common stock at a weighted average price of $11.1106 per share. According to the filing, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, and the sale was not at his discretion.
After this transaction, Frates directly beneficially owned 177,104 shares of Amylyx common stock. He also had indirect holdings through trusts, including 100,000 shares held by the JAMES M. FRATES 2025 GRAT No. 1 and additional blocks of 15,459 shares and 11,072 shares in other family trusts. For these trust holdings, he serves as trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.
Amylyx Pharmaceuticals, Inc. director and Co-Chief Executive Officer Joshua B. Cohen reported an automatic sale of common stock. On January 6, 2026, he sold 7,715 shares of Amylyx common stock at a weighted average price of $11.0948 per share. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the sales were automatic and not at his discretion.
After this transaction, Cohen beneficially owned 3,317,632 shares of Amylyx common stock, held directly.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported an automatic sale of 7,715 shares of common stock on January 6, 2026. The shares were sold at a weighted average price of $11.0939 per share to cover tax withholding obligations arising from the vesting of restricted stock units, and the sale was not made at his discretion.
After this tax-related sale, Klee beneficially owned 3,317,586 shares of Amylyx Pharmaceuticals, Inc. common stock directly.
Justin B. Klee, Co-Chief Executive Officer and a director of Amylyx Pharmaceuticals, Inc. (AMLX), reported sales of company common stock that were automatic to cover tax withholding on vested restricted stock units. On 09/30/2025 the reporting shows 29,775 shares sold at a weighted average price of $14.3728 and an additional 200 shares sold at a weighted average price of $15.01. After these transactions the filing reports total beneficial ownership of 3,325,301 shares (direct). The filing notes the sales were mandatory to satisfy tax obligations and were executed in multiple trades at prices within the disclosed ranges.
Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported the automatic sale of 8,828 shares of common stock to satisfy tax withholding related to the vesting of restricted stock units. The weighted average price reported for the sales was $14.5751, with execution prices ranging from $14.355 to $15.075. After the transaction, the filing shows the reporting person beneficially owns 148,141 shares. The filing notes the sales were automatic to cover tax obligations and not at the reporting person's discretion.
James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported a sale on 09/30/2025 of 10,558 shares of common stock at a weighted average price of $14.6477. The filing states the sales were automatic to cover tax withholding related to the vesting of restricted stock units and were not at the reporting person’s discretion. After the reported transactions, Mr. Frates beneficially owned 280,430 shares directly and held an additional 15,459 and 11,072 shares indirectly through two trusts for which he is trustee. The form is signed by an attorney-in-fact on 10/02/2025.
Joshua B. Cohen, Co‑Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX), reported two automatic sales of common stock tied to the vesting of restricted stock units on 09/30/2025. The Form 4 shows a sale of 29,733 shares at a weighted average price of $14.3433 and a sale of 200 shares at a weighted average price of $14.9975; the filings state those sales were automatic to satisfy tax withholding obligations. After the transactions the reporting person beneficially owned 3,325,347 shares according to the Form 4. The filing notes the trades occurred across multiple execution prices within the ranges disclosed and that detailed breakdowns can be provided to the SEC on request.
Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals (AMLX), reported automatic sales of 12,039 shares on 09/30/2025 to satisfy tax withholding from restricted stock unit vesting. The disclosure shows a weighted average sale price of $14.5791 (individual sale prices ranged from $14.35 to $15.04). After the reported transactions, the reporting person beneficially owns 182,336 shares, held directly. The filing notes the sales were automatic to cover tax obligations and not at the reporting person's discretion.